Clinical trials: Retinal Neovascularization
Retinopathy of Prematurity
Fasudil Eye Drop in Retinopathy Of Prematurity(ROP)
Eligible eyes are randomly assigned into two groups. Group A receive Fasudil eye drops (concentration 0.5 percent) twice daily. Group B, receive artificial tears drop with the same frequency.
- Trial name
- NCT04191954
- Testing
- Fasudil eye drops (concentration 0.5 percent), receive artificial tears drop
- Where
- Iran
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Shahid Beheshti University of Medical Sciences
Choroidal Neovascularization, Retinal Pigment Epithelial Detachment
Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration
The investigators hypothesize that it is safe and effective to treat patients with choroidal neovascularisation (abnormal blood vessels growing under the retina) secondary to causes other than age related macular degeneration…
- Trial name
- NCT01628354
- Testing
- Ranibizumab
- Where
- Australia
- Volunteers
- 49 people
- Sponsor
- University of Melbourne
Choroidal Neovascularization, Macular Degeneration
Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD
The purpose of this research study is to compare different timing therapies of Verteporfin with Bevacizumab to treat choroidal neovascularization (CNV) due to age-related macular degeneration (AMD).
- Trial name
- NCT00426998
- Testing
- Verteporfin, Bevacizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Retinal Consultants Medical Group
Age-Related Macular Degeneration, Neovascularization, Choroidal
Impact of Non-Exudative Type 1 MNV on AMD Progression
The overall goal of the proposed research project is to provide evidence that a specific subtype of neovascularization that may develop in eyes with age-related macular degeneration (AMD) prevents vision loss.
- Trial name
- NCT06125977
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- University of Utah
Age-Related Macular Degeneration
Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab
To determine if patients treated early after diagnosis of wet age-related macular degeneration can return/maintain to their baseline pre-disease BCVA.
- Trial name
- COMPASS (NCT01402544)
- Testing
- ranibizumab
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Diego
Retinal Neovascularization
Daily Testing at Home by NV-AMD Subjects With Notal Home OCT.
The purpose of this study is to evaluate the ability of subjects with NV-AMD to perform sequential daily self-imaging of their eyes with the self-operated Notal Home OCT device in their homes for 90 days without on-site…
- Trial name
- NCT04650672
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Notal Vision Inc.
Age Related Macular Degeneration, Choroidal Neovascularization
Home Vision Monitoring Using the ForeseeHome Device Following Treatment of Neovascular Age Related Macular Degeneration
ForeseeHome, an FDA-approved home device, was specifically designed for unsupervised Preferential-Hyperacuity-Perimeter (PHP) testing of Age Related Macular Degeneration (AMD) patients at home by characterizing central and…
- Trial name
- CNV (NCT01334294)
- Testing
- ForeseeHome
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Notal Vision Ltd.
Diabetic Retinopathy, Retinal Neovascularization
Krypton-Argon Regression of Neovascularization Study (KARNS)
To evaluate whether red krypton laser treatment is as effective at causing regression of diabetic disc neovascularization as treatment with the blue-green argon laser, when both lasers are used with identical panretinal…
- Conditions
- Diabetic Retinopathy, Retinal Neovascularization, Diabetes Mellitus
- Trial name
- NCT00000153
- Testing
- Blue-Green Argon Laser Treatment, Red Krypton Laser Treatment
- Sponsor
- National Eye Institute (NEI)
Macular Degeneration
Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration
This study will evaluate visual improvement in patients treated with Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) or placebo who have Age-Related Macular Degeneration (AMD) with occult…
- Trial name
- NCT00220805
- Testing
- Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP)
- Where
- 7 sites in Germany
- Volunteers
- 96 people
- Sponsor
- Grifols Therapeutics LLC
Macular Degeneration
Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)
The purpose of this study is to determine if Macugen™ reduces foveal thickness and improves vision in patients with wet AMD.
- Trial name
- NCT00087763
- Testing
- Macugen ™ (pegaptanib sodium injection)
- Volunteers
- 135 people
- Sponsor
- Eyetech Pharmaceuticals
Erectile Dysfunction
Fundus Oculi and Erectile Dysfunction
The purpose of this study is to evaluate the correlation between fundus oculi's vascularization in patients with erectile dysfunction and not, and, in the same patients, before and after using drugs for ED.
- Trial name
- NCT02845765
- Testing
- Dynamic Vessel Analyzer (DVA), Phosphodiesterase type 5 Inhibitor (PDE5I)
- Where
- Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ospedale San Raffaele
Choroidal Neovascularization
Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE)
The purpose of the study is to investigate the efficacy of a new drug called ranibizumab in the treatment of choroidal neovascularization in underlying angioid streaks due to Pseudoxanthoma elasticum.
- Trial name
- NCT00510965
- Testing
- Intravitreal injection ranibizumab
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- University Hospital, Bonn
Neovascular Age-related Macular Edema, Diabetic Macular Edema
Anti-VEGF in Real-world
Anti-vascular endothelial growth factor therapy is the major intervention for treating ischemic retina diseases. According to FDA and China Food and Drug Administration, Ranibizumab, Aflibercept, and Conbercept are major types of…
- Conditions
- Neovascular Age-related Macular Edema, Diabetic Macular Edema, Choroidal Neovascular Membrane, Non-proliferative Diabetic Retinopathy
- Trial name
- NCT05222633
- Testing
- Ranibizumab, Aflibercept, Conbercept
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Wenbin Wei
Age Related Macular Degeneration
Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) Patients
The purpose of the study is to provide efficacy and safety data for monthly ranibizumab 0.5 mg intravitreal injections in Chinese patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular…
- Trial name
- EXTEND II (NCT00826371)
- Testing
- ranibizumab 0.5 mg
- Where
- 6 sites in China
- Volunteers
- 114 people
- Sponsor
- Novartis Pharmaceuticals
Macular Degeneration, Age-Related Macular Degeneration
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person.
- Conditions
- Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
- Trial name
- TORRONTES (NCT07496567)
- Testing
- Tiespectus, Aflibercept
- Where
- 71 sites in United States, Brazil and 7 more
- Volunteers
- 960 people
- Sponsor
- EyeBiotech Ltd.
Age Related Macular Degeneration
Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).
The aim of the study is to evaluate whether PF-04523655 is effective in the treatment of neovascular/wet AMD and at which dose.
- Trial name
- MONET (NCT00713518)
- Testing
- 0.5 mg ranibizumab, 3 mg PF-04523655, 1 mg PF-04523655
- Where
- 31 sites in United States, Austria and 9 more
- Volunteers
- 152 people
- Sponsor
- Quark Pharmaceuticals
Neovascular (Wet) Age-related Macular Degeneration
Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications
This study is designed as an observational, non-interventional, multicenter, open label, single arm study in patients being treated with Lucentis® for any approved indication included in the local product posology.
- Trial name
- PACIFIC (NCT04847895)
- Testing
- Lucentis
- Where
- 175 sites in Germany, Netherlands and 1 more
- Volunteers
- 5,500 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age Related Macular Degeneration(nAMD)
A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of VIS-101 administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with…
- Trial name
- ASCEND (NCT07798375)
- Testing
- VIS-101 6.0mg Low concentration, VIS-101 6.0mg High concentration, VIS-101 9.0mg High concentration
- Volunteers
- 244 people
- Sponsor
- Everest Medicines (China) Co.,Ltd.
Electronic Cigarette Use, Retina; Change
Nicotine Influence on the Retina Following the Use of Electronic Cigarette
The marketing of electronic cigarettes (e-cigarettes) in 2003 was initially intended to present a healthier alternative to smokers.
- Trial name
- NCT05801419
- Testing
- RETI-port/scan 21, Zilia Ocular, OCT-A
- Where
- Canada
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Christian Casanova
Age-related Macular Degeneration
Characterization of Early Markers of Choroidal Neovascularization
To this study and identify the sequence of alterations occurring in the chorioretinal interface during progression of AMD from "dry" AMD to sight-threatening chorioretinal neovascularization (CNV).
- Trial name
- CNV-Markers (NCT00801541)
- Where
- Portugal
- Volunteers
- 60 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image